Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy
暂无分享,去创建一个
G. Damia | F. Ricci | M. Fratelli | L. Porcu | R. Fruscio | F. Spriano | T. Dell'anna | F. Guffanti